Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703196 · ClinicalTrials.gov registry record · Phase 2
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
A Phase 2 study of Cervical Cancer and Precancerous Condition, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 368
- Enrollment target
- 1
- Study location
NCT00703196: Completed Phase 2 study of Cervical Cancer and Precancerous Condition, sponsored by University of Alabama at Birmingham.
NCT00703196 is a Phase 2 study of Cervical Cancer and Precancerous Condition that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 368 participants, below the 568-participant average among 144 other Cervical Cancer trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00703196, a Phase 2 study of Cervical Cancer and Precancerous Condition, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 368 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Supplements, such as folic acid, may stop or delay the development of cervical cancer in women infected with human papillomavirus. PURPOSE: This phase II trial is studying how well folic acid supplements work in preventing cancer in women infected with human papillomavirus.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT folic acid
Study Locations (1)
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00703196 record still lists
NCT00703196 is an interventional study that assigns participants to a tested intervention. The registered 368 participants enrollment target is mid-sized for trials with a published cap, below the 568-participant average among 144 other Cervical Cancer trials with a reported enrollment target (35% lower).
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00703196 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT00703196 about?
NCT00703196 is a clinical study titled "Folic Acid Clinical Trial for the Prevention of Cervical Cancer". RATIONALE: Supplements, such as folic acid, may stop or delay the development of cervical cancer in women infected with human papillomavirus. PURPOSE: This phase II trial is studying how well folic acid supplements work in preventing cancer in women infected with human papillomavirus.
What is the current status of trial NCT00703196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 368 participants. The study started on 2007-03.
What conditions does trial NCT00703196 study?
This clinical trial studies the following conditions: Cervical Cancer, Precancerous Condition.
What interventions are being tested in trial NCT00703196?
The interventions under investigation include: placebo (OTHER), folic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00703196?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00703196 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00703196's enrollment target sits among peer trials
368 33rd of 144 higher than 112 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia